AR 12463

Drug Profile

AR 12463

Latest Information Update: 30 May 2005

Price : $50

At a glance

  • Originator UCB
  • Class Antihyperlipidaemics; Vasodilators
  • Mechanism of Action Cholesterol synthesis inhibitors; Thromboxane receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 31 Dec 2002 Discontinued - Preclinical for Thrombosis in Belgium (unspecified route)
  • 31 Dec 2002 Discontinued - Preclinical for Atherosclerosis in Belgium (unspecified route)
  • 31 Dec 2002 Discontinued - Preclinical for Ischaemic heart disorders in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top